Establishing a global regulatory floor for children’s decisions about participation in clinical research

Autor: Steven Joffe, Albert J. Allen, Jonathan M. Davis, Elisa Koppelman, Susan Z. Kornetsky, Grace Marie V. Ku, Victoria A. Miller, Jennifer Preston, Lesha D. Shah, Barbara E. Bierer

Publikováno v: Pediatric Research.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::34043a9cfe0f2c34623af343b790ef93
https://doi.org/10.1038/s41390-023-02483-8

Efficacy and Safety of Atomoxetine Hydrochloride in Asian Adults With ADHD

Autor: Michihiro Takahashi, Taro Goto, Hironobu Ichikawa, Susan Shur-Fen Gau, Yasushi Takita, Paula T. Trzepacz, Yuko Hirata, Albert J. Allen, Dong-Ho Song

Publikováno v: Journal of Attention Disorders. 21:100-109

Objective: The efficacy and safety of atomoxetine was assessed in adult ADHD patients from Japan, Korea, and Taiwan in this first placebo-controlled Asian clinical study in adults of an ADHD medication. Method: Atomoxetine was compared with placebo (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c703c4a236d630bc8f5a5f60197723ff
https://doi.org/10.1177/1087054713510352

A Pharmaceutical Bioethics Consultation Service: Six-Year Descriptive Characteristics and Results of a Feedback Survey

Autor: Susan B. Watson, Albert J. Allen, Donald G. Therasse, Luann E. Van Campen

Publikováno v: Ajob Empirical Bioethics

Background: Bioethics consultations are conducted in varied settings, including hospitals, universities, and other research institutions, but there is sparse information about bioethics consultations conducted in corporate settings such as pharmaceut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f83d347efa0c1da47a94c3965a0e1ec1
https://doi.org/10.1080/23294515.2014.957363

Safety and tolerability of atomoxetine hydrochloride in a long-term, placebo-controlled randomized withdrawal study in European and non-European adults with attention-deficit/hyperactivity disorder

Autor: David R. Williams, J. Antoni Ramos-Quiroga, Jeannine R. Lane, Albert J. Allen, Yoko Tanaka, Rodrigo Escobar, A. Camporeale, Himanshu P. Upadhyaya, Paula T. Trzepacz

Publikováno v: The European Journal of Psychiatry, Volume: 27, Issue: 3, Pages: 206-224, Published: SEP 2013
The European Journal of Psychiatry v.27 n.3 2013
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname

� Background and Objectives: Safety and tolerability of atomoxetine were studied in the largest double-blind, placebo-controlled, randomised withdrawal trial of atomoxetine (80 or 100 mg/day) in adults with attention-deficit/hyperactivity disorder

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::596bf10787667704406e9a2f059bc03c
https://doi.org/10.4321/s0213-61632013000300005

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

Autor: David O. Calligaro, Eric S. Nisenbaum, Kory Schuh, Leslie M. Schuh, Mary Jeanne Kallman, Todd M. Durell, Himanshu P. Upadhyaya, Warren K. Bickel, Paula T. Trzepacz, Albert J. Allen, Frank P. Bymaster, Paul J. Emmerson, Clarke David O, Durisala Desaiah

Publikováno v: Psychopharmacology

Rationale Treatment of attention-deficit/hyperactivity disorder (ADHD) has for many years relied on psychostimulants, particularly various formulations of amphetamines and methylphenidate. These are central nervous system stimulants and are scheduled

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abba3e26621f5c5896b55cf76deeab1a
https://doi.org/10.1007/s00213-013-2986-z